we have seen a 50% increase in testing volumes. between those two. and we don t quite know if we re at peak yet with omicron. reporter: and jake, i also checked in with the florida hospital association. they say they re seeing hospitalizations relatively low increasing slowly, but they still have many beds to treat covid patients and non-covid patients in florida. are they worried at all about running out of tests? so i asked about supply, and they say at this point, while they don t know exactly when they will hit the peak for this omicron wave, the head of nomi health in florida says they are not concerned about supply when it comes to testing materials. they are working around the clock when it comes to their labs, but the supply is not a concern at this point. leyla santiago in miami,
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global newborn screening market size is projected to reach USD 1.3 billion by 2026 from USD 0.9 billion in 2021, at a CAGR of 8.3% during the forecast period.
The rapid growth in the newborn screening rate, the increasing prevalence of newborn metabolic, hormonal and genetic diseases, and favourable government policies are driving the growth of newborn screening.
Newborn Disorder screening instruments segment accounted for the largest share of the newborn screening market in 2019.
Based on instrument, the newborn screening market is segmented into newborn disorder screening instruments, newborn hearing screening instruments, and pulse oximeters. Newborn disorder screening instruments accounted for the largest share in 2019. These instruments can screen for the majority of newborn disorders and thus see the highest demand. Government support and the implementation of newborn screening programs also supp